価格表

在庫・価格 : 2025年05月15日 11時00分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-Phospho MCM2 (S53), Rabbit-Poly
データシート
A300-756A BETベチル ラボラトリーズ
Bethyl Laboratories, Inc.
0.1 ml ¥109,000
(未発注)
追加

在庫・価格 : 2025年05月15日 11時00分 現在

Anti-Phospho MCM2 (S53), Rabbit-Poly

  • 商品コード:A300-756A
  • メーカー:BET
  • 包装:0.1ml
  • 価格: ¥109,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Kulkarni AA et al. Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma. Clin. Cancer Res. 2009 Apr;15(7):2417-25
Kulkarni AA et al
2009/01/01
PubMed
2 Cremona CA et al. Loss of anchorage in checkpoint-deficient cells increases genomic instability and promotes oncogenic transformation. J. Cell. Sci. 2009 Sep;122(Pt 18):3272-81
Cremona CA et al
2009/01/01
PubMed
3 Hughes S et al. Transcriptional co-activator LEDGF interacts with Cdc7-activator of S-phase kinase (ASK) and stimulates its enzymatic activity. J. Biol. Chem. 2010 Jan;285(1):541-54
Hughes S et al
2010/01/01
PubMed
4 Rodriguez-Acebes S et al. Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers. Am. J. Pathol. 2010 Oct;177(4):2034-45
Rodriguez-Acebes S et al
2010/01/01
PubMed
5 Kitamura R et al. Molecular mechanism of activation of human Cdc7 kinase: bipartite interaction with Dbf4/activator of S phase kinase (ASK) activation subunit stimulates ATP binding and substrate recognition. J. Biol. Chem. 2011 Jul;286(26):23031-43
Kitamura R et al
2011/01/01
PubMed
6 Yamazaki S et al. Rif1 regulates the replication timing domains on the human genome. EMBO J. 2012 Sep;31(18):3667-77
Yamazaki S et al
2012/01/01
PubMed
7 Sasi NK et al. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds. PLoS ONE 2014;9(11):e113300
Sasi NK et al
2014/01/01
PubMed
  • No.: 1
  • 文献情報:
    Kulkarni AA et al. Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma. Clin. Cancer Res. 2009 Apr;15(7):2417-25
    Kulkarni AA et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Cremona CA et al. Loss of anchorage in checkpoint-deficient cells increases genomic instability and promotes oncogenic transformation. J. Cell. Sci. 2009 Sep;122(Pt 18):3272-81
    Cremona CA et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Hughes S et al. Transcriptional co-activator LEDGF interacts with Cdc7-activator of S-phase kinase (ASK) and stimulates its enzymatic activity. J. Biol. Chem. 2010 Jan;285(1):541-54
    Hughes S et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Rodriguez-Acebes S et al. Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers. Am. J. Pathol. 2010 Oct;177(4):2034-45
    Rodriguez-Acebes S et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Kitamura R et al. Molecular mechanism of activation of human Cdc7 kinase: bipartite interaction with Dbf4/activator of S phase kinase (ASK) activation subunit stimulates ATP binding and substrate recognition. J. Biol. Chem. 2011 Jul;286(26):23031-43
    Kitamura R et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Yamazaki S et al. Rif1 regulates the replication timing domains on the human genome. EMBO J. 2012 Sep;31(18):3667-77
    Yamazaki S et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Sasi NK et al. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds. PLoS ONE 2014;9(11):e113300
    Sasi NK et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed